Pharmalot

By  Ed Silverman

Taking stock of the drug industry, from the lab to the medicine chest. Sign up for the newsletter here.

Pharmalot

Justice Department tells Supreme Court it wants to scuttle a whistleblower case against Gilead

By Ed Silverman

Pharmalot

Pharmalittle: Glaxo buys Tesaro for $5.1 billion; showdown as Takeda deal for Shire nears

By Ed Silverman

Pill illo
Pharmalot

As pharma seeks more orphan drug designations, FDA fails to assess important needed info

By Ed Silverman

Amazon logo
Pharmalot

As Amazon moves into the pharmacy business, licensing efforts gain scrutiny

By Ed Silverman

Taxes Health Care Q&A
Pharmalot

Big drug makers are socking away more cash lately thanks to the tax overhaul, and it’s likely to be used for more deals

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Will a judge nix the CVS-Aetna deal? Takeda to sell billions in assets to pay for Shire

By Ed Silverman

Pharmalot

Pharmalittle: Merck boosts prices on a few drugs; former Insys execs pleads guilty in Subsys conspiracy

By Ed Silverman

Truvada bottle and pills
Pharmalot

Once-a-day pills for combating HIV are a better deal than some people think

By Ed Silverman

German Pharma
Pharmalot

Boehringer Ingelheim abandons biosimilar sales outside the U.S.

By Ed Silverman

Pharmalot
Pharmalot

Philadelphia becomes the latest city to consider licensing sales reps to blunt the opioid crisis

By Ed Silverman

Pharmalot

Pharmalittle: Former Takeda chairman opposes Shire deal; FDA says intensity and duration of shortages is spiking

By Ed Silverman

Generic epinephrine
Pharmalot

FDA promised a ‘lower-cost option’ to EpiPen, but the price isn’t any lower

By Ed Silverman

Pharmalot

Pharmalittle: Trump team proposes some Medicare changes; Bristol-Myers cancer drug fails another trial

By Ed Silverman

Patient is meeting a doctor
Pharmalot

Pharma-backed group attacks a controversial cost-shifting insurance tool by scaring employers

By Ed Silverman

Pills drug pricing
Pharmalot

Pharma reaches a tentative deal with the U.K. over pricing and access

By Ed Silverman

Pharmalot

Pharmalittle: Novartis pricing is being tested; Trump team looks to relax kickback rules

By Ed Silverman

Close-up eye
Pharmalot

Roche and Novartis lose a court battle in Europe over off-label use of repackaged drugs

By Ed Silverman

insulin
Pharmalot

Senators press insurers for reams of pricing and rebate info on insulin

By Ed Silverman

Mylan
Pharmalot

Mylan is scolded by the FDA for manufacturing gaffes at a key plant

By Ed Silverman

Pharmalot

Pharmalittle: FDA still has concerns about compounders; Takeda bid for Shire wins advisory backing

By Ed Silverman

HIV prevention pill Truvada
Pharmalot

Panel recommends everyone at high risk of getting HIV be offered a prevention pill

By Ed Silverman

Malaria - South Sudan
Pharmalot

Only a few drug makers are actively targeting medicines needed in poor countries

By Ed Silverman

Pharmalot

Pharmalittle: FDA to reduce use of dogs in tests; another setback for a Pfizer immunotherapy drug

By Ed Silverman

Mail bag
Pharmalot

You have questions on biosimilars. We have answers

By Nicholas Florko and Ed Silverman

Kaleo Naloxone Donation 02
Pharmalot

A drug maker boosted the price of its opioid-overdose antidote by 600 percent, and taxpayers suffered

By Ed Silverman

Pharmalot

HHS watchdog chastises Mallinckrodt over a giveaway program for its pricey Acthar Gel drug

By Ed Silverman

Pharmalot

Pharmalittle: AstraZeneca plans for its next CEO; FDA struggles with questions over drug costs

By Ed Silverman

Epi-Pen for June 22
Pharmalot

EpiPen may have a lot of value … but only if it costs $24

By Ed Silverman

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy